Select Your Location:

SEQUOIA 5-Year Follow-Up in Arm C: Frontline Zanubrutinib Monotherapy in Patients With del(17p) and Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma